Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Skeletal | 17 | 2025 | 308 | 3.180 |
Why?
|
| Lipid Metabolism | 14 | 2023 | 140 | 2.930 |
Why?
|
| Diabetes Mellitus, Type 2 | 13 | 2023 | 744 | 2.800 |
Why?
|
| Insulin Resistance | 15 | 2020 | 199 | 2.750 |
Why?
|
| Electric Stimulation Therapy | 3 | 2025 | 17 | 2.610 |
Why?
|
| Mitochondria, Muscle | 8 | 2017 | 23 | 2.110 |
Why?
|
| Muscle Fibers, Skeletal | 11 | 2018 | 70 | 2.030 |
Why?
|
| Exercise | 11 | 2022 | 674 | 1.960 |
Why?
|
| Resistance Training | 2 | 2025 | 20 | 1.600 |
Why?
|
| Hyperglycemia | 2 | 2025 | 60 | 1.580 |
Why?
|
| Obesity | 11 | 2025 | 1129 | 1.150 |
Why?
|
| Carbohydrate Metabolism | 1 | 2025 | 26 | 0.930 |
Why?
|
| Muscle Strength | 1 | 2025 | 36 | 0.870 |
Why?
|
| Quadriceps Muscle | 4 | 2025 | 8 | 0.860 |
Why?
|
| Overweight | 1 | 2025 | 248 | 0.770 |
Why?
|
| Adult | 26 | 2025 | 13437 | 0.680 |
Why?
|
| Medical History Taking | 1 | 2020 | 37 | 0.640 |
Why?
|
| Young Adult | 17 | 2023 | 4928 | 0.620 |
Why?
|
| Motor Activity | 4 | 2015 | 438 | 0.580 |
Why?
|
| Humans | 35 | 2025 | 42113 | 0.560 |
Why?
|
| Male | 25 | 2025 | 22745 | 0.560 |
Why?
|
| Physical Fitness | 3 | 2020 | 93 | 0.540 |
Why?
|
| Nucleosomes | 1 | 2017 | 31 | 0.530 |
Why?
|
| Vesicular Transport Proteins | 2 | 2014 | 47 | 0.520 |
Why?
|
| Adipose Tissue | 6 | 2017 | 180 | 0.510 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 531 | 0.500 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 49 | 0.490 |
Why?
|
| Physical Endurance | 4 | 2025 | 20 | 0.490 |
Why?
|
| Sirtuins | 1 | 2015 | 14 | 0.480 |
Why?
|
| MicroRNAs | 1 | 2022 | 501 | 0.480 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 71 | 0.460 |
Why?
|
| Energy Metabolism | 6 | 2025 | 181 | 0.460 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 181 | 0.440 |
Why?
|
| Blood Glucose | 3 | 2025 | 386 | 0.430 |
Why?
|
| Coatomer Protein | 1 | 2014 | 1 | 0.430 |
Why?
|
| Oxygen Consumption | 5 | 2018 | 111 | 0.420 |
Why?
|
| Phosphoproteins | 1 | 2015 | 201 | 0.410 |
Why?
|
| Electric Stimulation | 2 | 2025 | 198 | 0.410 |
Why?
|
| DNA Methylation | 1 | 2017 | 393 | 0.410 |
Why?
|
| Carrier Proteins | 1 | 2015 | 318 | 0.400 |
Why?
|
| Glucose Clamp Technique | 4 | 2020 | 7 | 0.350 |
Why?
|
| Middle Aged | 9 | 2025 | 11790 | 0.340 |
Why?
|
| Cells, Cultured | 7 | 2017 | 1617 | 0.330 |
Why?
|
| Muscle Fibers, Slow-Twitch | 3 | 2015 | 10 | 0.320 |
Why?
|
| Body Composition | 4 | 2020 | 160 | 0.320 |
Why?
|
| Lipids | 2 | 2023 | 256 | 0.250 |
Why?
|
| Physical Conditioning, Animal | 2 | 2025 | 32 | 0.240 |
Why?
|
| Female | 13 | 2025 | 23980 | 0.240 |
Why?
|
| Body Mass Index | 5 | 2013 | 915 | 0.230 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2025 | 3 | 0.230 |
Why?
|
| Choristoma | 2 | 2017 | 4 | 0.230 |
Why?
|
| Oxidative Phosphorylation | 2 | 2015 | 56 | 0.220 |
Why?
|
| Insulin | 5 | 2017 | 255 | 0.210 |
Why?
|
| Glycogen | 3 | 2018 | 20 | 0.200 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2023 | 14 | 0.200 |
Why?
|
| Glycerophospholipids | 1 | 2022 | 4 | 0.200 |
Why?
|
| Health Services | 1 | 2023 | 62 | 0.200 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 20 | 0.190 |
Why?
|
| Triglycerides | 3 | 2013 | 146 | 0.180 |
Why?
|
| Diglycerides | 2 | 2013 | 9 | 0.180 |
Why?
|
| RNA, Messenger | 3 | 2023 | 1265 | 0.170 |
Why?
|
| Exercise Therapy | 2 | 2020 | 83 | 0.170 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 239 | 0.160 |
Why?
|
| Cross-Sectional Studies | 6 | 2015 | 3073 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 290 | 0.160 |
Why?
|
| Biopsy | 3 | 2017 | 176 | 0.160 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 1066 | 0.160 |
Why?
|
| Adenosine Triphosphate | 3 | 2016 | 205 | 0.160 |
Why?
|
| Prognosis | 1 | 2022 | 847 | 0.150 |
Why?
|
| Palmitic Acid | 2 | 2018 | 23 | 0.150 |
Why?
|
| Oxidation-Reduction | 4 | 2014 | 448 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 137 | 0.150 |
Why?
|
| Liver | 3 | 2016 | 503 | 0.140 |
Why?
|
| Ceramides | 3 | 2013 | 43 | 0.140 |
Why?
|
| Mexican Americans | 1 | 2020 | 224 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 928 | 0.130 |
Why?
|
| Aged | 3 | 2023 | 7958 | 0.130 |
Why?
|
| Lipolysis | 2 | 2014 | 20 | 0.130 |
Why?
|
| Fatty Acids | 3 | 2012 | 134 | 0.120 |
Why?
|
| Weight Gain | 2 | 2014 | 138 | 0.120 |
Why?
|
| Double-Blind Method | 1 | 2016 | 305 | 0.120 |
Why?
|
| ADP Ribose Transferases | 1 | 2015 | 7 | 0.120 |
Why?
|
| Adiposity | 3 | 2014 | 155 | 0.120 |
Why?
|
| Caloric Restriction | 1 | 2015 | 34 | 0.120 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 38 | 0.120 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 83 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 534 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 274 | 0.110 |
Why?
|
| Overnutrition | 1 | 2014 | 6 | 0.110 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2014 | 27 | 0.110 |
Why?
|
| Epinephrine | 1 | 2014 | 37 | 0.110 |
Why?
|
| Longevity | 1 | 2015 | 167 | 0.100 |
Why?
|
| Glucose | 2 | 2012 | 242 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 29 | 0.100 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2013 | 9 | 0.100 |
Why?
|
| Adolescent | 3 | 2020 | 5949 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 129 | 0.100 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2012 | 12 | 0.100 |
Why?
|
| Glucose Tolerance Test | 2 | 2012 | 76 | 0.100 |
Why?
|
| Phenotype | 1 | 2015 | 774 | 0.100 |
Why?
|
| Energy Intake | 1 | 2013 | 162 | 0.100 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2012 | 7 | 0.090 |
Why?
|
| Carnitine O-Acetyltransferase | 1 | 2012 | 1 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 59 | 0.090 |
Why?
|
| Physical Exertion | 1 | 2012 | 27 | 0.090 |
Why?
|
| Muscular Diseases | 1 | 2011 | 22 | 0.090 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 41 | 0.090 |
Why?
|
| Citrate (si)-Synthase | 1 | 2011 | 10 | 0.090 |
Why?
|
| Body Weight | 2 | 2013 | 428 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 5 | 0.090 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 8 | 0.090 |
Why?
|
| Thermogenesis | 1 | 2011 | 24 | 0.080 |
Why?
|
| Exercise Test | 1 | 2011 | 75 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 80 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2011 | 117 | 0.080 |
Why?
|
| Mice, Knockout | 3 | 2025 | 1010 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 112 | 0.080 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2009 | 6 | 0.080 |
Why?
|
| Mice | 5 | 2025 | 6490 | 0.080 |
Why?
|
| Lipase | 1 | 2009 | 18 | 0.080 |
Why?
|
| Anaerobic Threshold | 1 | 2009 | 4 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2009 | 48 | 0.070 |
Why?
|
| Calcium | 1 | 2011 | 487 | 0.070 |
Why?
|
| Homeostasis | 1 | 2009 | 191 | 0.070 |
Why?
|
| Diet | 1 | 2013 | 810 | 0.070 |
Why?
|
| Animals | 7 | 2025 | 16694 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 661 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 1804 | 0.050 |
Why?
|
| Ionomycin | 2 | 2016 | 11 | 0.050 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2017 | 41 | 0.050 |
Why?
|
| Genes, Switch | 1 | 2022 | 3 | 0.050 |
Why?
|
| Mitochondria | 3 | 2012 | 516 | 0.050 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2022 | 10 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2025 | 173 | 0.050 |
Why?
|
| Myocardium | 1 | 2025 | 250 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 159 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2025 | 2111 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 660 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 73 | 0.030 |
Why?
|
| Palmitates | 1 | 2016 | 15 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2016 | 18 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 74 | 0.030 |
Why?
|
| Myostatin | 1 | 2016 | 61 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2016 | 110 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 165 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2014 | 21 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 167 | 0.030 |
Why?
|
| Adipocytes | 1 | 2014 | 58 | 0.030 |
Why?
|
| Dietetics | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2012 | 35 | 0.020 |
Why?
|
| Rest | 1 | 2012 | 33 | 0.020 |
Why?
|
| Electron Transport | 1 | 2012 | 45 | 0.020 |
Why?
|
| Acetyl Coenzyme A | 1 | 2012 | 8 | 0.020 |
Why?
|
| Carnitine | 1 | 2012 | 8 | 0.020 |
Why?
|
| Leptin | 1 | 2013 | 118 | 0.020 |
Why?
|
| Acetylcarnitine | 1 | 2012 | 7 | 0.020 |
Why?
|
| Eating | 1 | 2013 | 164 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 733 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 74 | 0.020 |
Why?
|
| Fasting | 1 | 2011 | 56 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2011 | 62 | 0.020 |
Why?
|
| Carbon | 1 | 2012 | 127 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2011 | 23 | 0.020 |
Why?
|
| Ion Channels | 1 | 2011 | 74 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 223 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 173 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 1570 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 158 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 71 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 1582 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 534 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 633 | 0.020 |
Why?
|
| Myoblasts | 1 | 2009 | 30 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 526 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 59 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 649 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 278 | 0.020 |
Why?
|
| Sports | 1 | 2009 | 53 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 729 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 884 | 0.020 |
Why?
|
| Life Style | 1 | 2009 | 326 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2007 | 68 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 1845 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1004 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 2790 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2009 | 722 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 2466 | 0.010 |
Why?
|